Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Team Grant - HIV/AIDS and comorbidities - LOI

University of British Columbia

$8,750.00

Molecular Aging and HIV co-morbidities in Women and Children

FY 2011-12

Summary
Globally, ~3 million HIV+ women give birth each year. Although currently ~2.5 million children are infected with HIV, HIV-exposed uninfected (HEU) children now outnumber them. Treating HIV-infected pregnant women and their newborn infants with antiretroviral therapy greatly reduces perinatal transmission from ~25% to ~1%. However, little is known about the long-term health of HEU and HIV+ children exposed to antiretroviral drugs during early development, as these drugs have many toxicities. However, HEU children show unexplained increased infectious morbidity and mortality compared to control children. HIV-infected individuals also appear to age faster than the general population. There are many possible reasons for this. Among them are the shortening of telomeres (the structures that protect the ends of chromosomes), and damage to mitochondrial DNA (leading to mitochondrial dysfunction). Both can happen through HIV infection-related chronic inflammation/immune activation, as well as antiretroviral therapy-related mitochondrial toxicity. As accelerated telomere shortening and mitochondrial DNA mutations have been associated with aging, these could be mechanisms influencing co-morbidities seen in HIV-infected people that are normally associated with advancing age. Exposure to HIV and antiretroviral therapy during pregnancy or post-natal prophylaxis could also affect HEU children born to HIV+ mothers. Our team will study molecular markers of aging (telomeres and mitochondrial DNA) in women, pregnant women, and children (HIV+ and HEU) and relate these to antiretroviral drug exposure and various aging phenotypes.
Program
Team Grant - HIV/AIDS and comorbidities - LOI
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
247304
Name
Côté Hélène
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
HIV/AIDS and Co-morbidities
Projecttitle
Molecular Aging and HIV co-morbidities in Women and Children
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$8,750
Cihrequipment2
$0
Programname2
Team Grant - HIV/AIDS and comorbidities - LOI
Keyworddelim
Hiv And Aging; Hiv Co-Morbidities; Mitochondrial Dna Damage; Telomere Shortening
Abstract
Globally, ~3 million HIV+ women give birth each year. Although currently ~2.5 million children are infected with HIV, HIV-exposed uninfected (HEU) children now outnumber them. Treating HIV-infected pregnant women and their newborn infants with antiretroviral therapy greatly reduces perinatal transmission from ~25% to ~1%. However, little is known about the long-term health of HEU and HIV+ children exposed to antiretroviral drugs during early development, as these drugs have many toxicities. However, HEU children show unexplained increased infectious morbidity and mortality compared to control children. HIV-infected individuals also appear to age faster than the general population. There are many possible reasons for this. Among them are the shortening of telomeres (the structures that protect the ends of chromosomes), and damage to mitochondrial DNA (leading to mitochondrial dysfunction). Both can happen through HIV infection-related chronic inflammation/immune activation, as well as antiretroviral therapy-related mitochondrial toxicity. As accelerated telomere shortening and mitochondrial DNA mutations have been associated with aging, these could be mechanisms influencing co-morbidities seen in HIV-infected people that are normally associated with advancing age. Exposure to HIV and antiretroviral therapy during pregnancy or post-natal prophylaxis could also affect HEU children born to HIV+ mothers. Our team will study molecular markers of aging (telomeres and mitochondrial DNA) in women, pregnant women, and children (HIV+ and HEU) and relate these to antiretroviral drug exposure and various aging phenotypes.
Competitiondate
201111
Approvedterm2
1 yr 0 mth
Pinamesdelim
Côté, Hélène; Bitnun, Sean A; Money, Deborah M; Pick, Neora; Soudeyns, Hugo
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $8,750~ $0~
University of British Columbia - $8,750 Grant (2011-1… | Canada Spends